Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term cohort study of bivalent HPV vaccination, HPV infection, and immune status in girls eligible for the Dutch national HPV immunization program
NL-OMON54728Recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Mar 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine in human papillomavirus infection (4 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoints: HPV16/18 DNA positivity in vaginal self-sample, HPV16/18 viral load and 4 more. Started Mar 2009; status: recruiting.
02
Drugs
Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON54728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54728.